Evidence map›Paper›PMID 35033903›Full record

ArticleBiomaterials2022

Ink-jet 3D printing as a strategy for developing bespoke non-eluting biofilm resistant medical devices.

Yinfeng He, Jeni Luckett, Belen Begines, Jean-Frédéric Dubern, Andrew L Hook, Elisabetta Prina, Felicity R A J Rose, Christopher J Tuck, Richard J M Hague, Derek J Irvine and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Biomaterials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Exploiting Generative Design for 3D Printing of Bacterial Biofilm Resistant Composite Devices.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Yinfeng HeFaculty of Engineering, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom.
Jeni LuckettSchool of Life Sciences, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom.
Belen BeginesDepartment of Organic and Medicinal Chemistry, School of Pharmacy, University of Seville, Seville, 41012, Spain.
Jean-Frédéric DubernSchool of Life Sciences, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom.
Andrew L HookSchool of Pharmacy, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom.
Elisabetta PrinaBiodiscovery Institute, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom; School of Pharmacy, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom.
Felicity R A J RoseBiodiscovery Institute, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom; School of Pharmacy, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom.
Christopher J TuckFaculty of Engineering, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom.
Richard J M HagueFaculty of Engineering, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom.
Derek J IrvineFaculty of Engineering, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom.
Paul WilliamsSchool of Life Sciences, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom; Biodiscovery Institute, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom; National Biofilm Innovation Centre, University of Nottingham, Nottingham, NG7 2RD, United Kingdom. Electronic address: paul.williams@nottingham.ac.uk.
Morgan R AlexanderSchool of Pharmacy, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom; National Biofilm Innovation Centre, University of Nottingham, Nottingham, NG7 2RD, United Kingdom. Electronic address: morgan.alexander@nottingham.ac.uk.
Ricky D WildmanFaculty of Engineering, University of Nottingham, University Park, Nottingham, NG7 2RD, United Kingdom. Electronic address: ricky.wildman@nottingham.ac.uk.
University of Nottingham · GBUniversidad de Sevilla · ES

Funding

Medical Research Council MC_G0802525Wellcome Trust 103882Wellcome Trust 103882/Z/14/ZWellcome Trust 103884Wellcome Trust 103884/Z/14/Z
6 · The paper itself

Abstract

Chronic infection as a result of bacterial biofilm formation on implanted medical devices is a major global healthcare problem requiring new biocompatible, biofilm-resistant materials. Here we demonstrate how bespoke devices can be manufactured through ink-jet-based 3D printing using bacterial biofilm inhibiting formulations without the need for eluting antibiotics or coatings. Candidate monomers were formulated and their processability and reliability demonstrated. Formulations for in vivo evaluation of the 3D printed structures were selected on the basis of their in vitro bacterial biofilm inhibitory properties and lack of mammalian cell cytotoxicity. In vivo in a mouse implant infection model, Pseudomonas aeruginosa biofilm formation on poly-TCDMDA was reduced by ∼99% when compared with medical grade silicone. Whole mouse bioluminescence imaging and tissue immunohistochemistry revealed the ability of the printed device to modulate host immune responses as well as preventing biofilm formation on the device and infection of the surrounding tissues. Since 3D printing can be used to manufacture devices for both prototyping and clinical use, the versatility of ink-jet based 3D-printing to create personalised functional medical devices is demonstrated by the biofilm resistance of both a finger joint prosthetic and a prostatic stent printed in poly-TCDMDA towards P. aeruginosa and Staphylococcus aureus.

Indexed as

BiofilmsInkAnimalsBacteriaBiocompatible MaterialsMammalsMicePrinting, Three-DimensionalPseudomonas aeruginosaReproducibility of ResultsStaphylococcus aureusBiocompatible Materials3d printingBiofilmsCell instructive behaviourInk-jetMedical devices

Identifiers

PMID35033903
PMCPMC7613459
OpenAlexW4200363443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.